Novonesis provides outlook for 2024 with expected 5-7% organic sales growth and ~35% adj. EBITDA margin. Pro forma financials disclosed. Ester Baiget, CEO of Novonesis, said: “Today we provide key pro ...
PLAINVIEW, NY – Vaso Corporation (OTCQX:VASO), a medical device company, disclosed unaudited pro forma financial information today, following its earlier announcement regarding a proposed business ...
Masimo Corporation (NASDAQ:MASI), currently trading at $142.94, filed an amendment Monday to its previous Form 8-K, providing unaudited pro forma financial statements following the completion of its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results